Landmark day for Akcea as NICE recommends Tegsedi in rare inherited hATTR

‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR

The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.

More From BioPortfolio on "‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR"